Status:
UNKNOWN
A Pharmacogenomics Study of Safety and Efficacy of Enalapril or Enalapril-Folic Acid Therapy in Hypertensive Patients.
Lead Sponsor:
Cui Yimin
Conditions:
Enalapril Adverse Reaction
Pharmacogenomics
Eligibility:
All Genders
18+ years
Brief Summary
Dry cough is the most common adverse reaction of angiotensin converting enzyme, including enalapril, in Chinese population. Clinical observations suggest that the incidence of ACEI-induced dry cough i...
Eligibility Criteria
Inclusion
- Patients taking enalapril or enalapril-folic acid therapy
- Signed informed consent.
Exclusion
- Patients not taking enalapril treated
- Intolerance or unwillingness to blood sample collection.
Key Trial Info
Start Date :
August 16 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
2200 Patients enrolled
Trial Details
Trial ID
NCT03259399
Start Date
August 16 2017
End Date
June 1 2020
Last Update
August 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034